Pegavision Corporation (TPE:6491)
Taiwan
· Delayed Price · Currency is TWD 346.00
+1.00 (0.29%)
May 14, 2025, 9:43 AM CST
Pegavision Revenue
Pegavision had revenue of 1.59B TWD in the quarter ending March 31, 2025, a decrease of -7.63%. This brings the company's revenue in the last twelve months to 6.69B, down -5.24% year-over-year. In the year 2024, Pegavision had annual revenue of 6.82B with 0.40% growth.
Revenue (ttm)
6.69B
Revenue Growth
-5.24%
P/S Ratio
4.03
Revenue / Employee
n/a
Employees
n/a
Market Cap
26.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.82B | 27.44M | 0.40% |
| Dec 31, 2023 | 6.79B | 468.66M | 7.41% |
| Dec 31, 2022 | 6.32B | 726.16M | 12.98% |
| Dec 31, 2021 | 5.60B | 1.62B | 40.64% |
| Dec 31, 2020 | 3.98B | 623.28M | 18.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 11.34B |
| Caliway Biopharmaceuticals | 40.47M |
| Bora Pharmaceuticals Co., LTD. | 19.25B |
| Lotus Pharmaceutical | 19.12B |
| Polaris Group | 107.00M |
| Oneness Biotech | 117.93M |
| Lumosa Therapeutics | 43.59M |
| Center Laboratories | 1.62B |